Endothelial dysfunction in diabetes and hypertension: Cross talk in RAS, BMP4, and ROS-dependent COX-2-derived prostanoids

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 3, 2013, Pages 204-214

  Wong, Wing Tak ^a   Tian, Xiao Yu ^b   Huang, Yu ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BMP4; COX 2; endothelial dysfunction; RAS; ROS

Indexed keywords

ALISKIREN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; BONE MORPHOGENETIC PROTEIN 4; CAPTOPRIL; CILAZAPRIL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOSINOPRIL; INDOMETACIN; NITRIC OXIDE; OLMESARTAN; OXIDOREDUCTASE; PROSTAGLANDIN SYNTHASE; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; APOPTOSIS; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; CARDIOVASCULAR FUNCTION; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFE EXTENSION; LONG TERM CARE; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; SHEAR STRESS; SIGNAL TRANSDUCTION; SMOKING; STREPTOZOCIN DIABETES; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; CYCLOOXYGENASE 2; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; OXIDATIVE STRESS; PROSTAGLANDINS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 84875223674     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31827fe46e     Document Type: Review

References (136)

1. Rajagopalan S, Harrison DG. Reversing endothelial dysfunction with ace inhibitors. A new trend. Circulation. 1996;94:240-243.
2. Capers Q, Laursen JB, Fukui T, et al. Vascular thrombin receptor regulation in hypertensive rats. Circ Res. 1997;80:838-844.
3. Giacchetti G, Sechi LA, Rilli S, et al. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120-126.
4. Aguilar D, Solomon SD. Ace inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme. Drugs. 2006;66:1169-1177.
5. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens. 2006;24:11-25.
6. Dorenkamp M, Riad A, Stiehl S, et al. Protection against oxidative stress in diabetic rats: role of angiotensin at(1) receptor and beta 1-adrenoceptor antagonism. Eur J Pharmacol. 2005;520:179-187.
7. Kanno S, Wu YJ, Lee PC, et al. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation. 2001;104:945-950.
8. Yagi S, Morita T, Katayama S. Combined treatment with an at1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res. 2004;27:129-135.
9. Ungvari Z, Csiszar A, Kaminski PM, et al. Chronic high pressure-induced arterial oxidative stress: involvement of protein kinase c-dependent nad(p) h oxidase and local renin-angiotensin system. Am J Pathol. 2004;165: 219-226.
10. Sorescu GP, Song H, Tressel SL, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95: 773-779.
11. Sorescu GP, Sykes M, Weiss D, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem. 2003;278:31128-31135.
12. Kiyono M, Shibuya M. Bone morphogenetic protein 4 mediates apoptosis of capillary endothelial cells during rat pupillary membrane regression. Mol Cell Biol. 2003;23:4627-4636.
13. Miriyala S, Gongora Nieto MC, Mingone C, et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular nadph oxidases, and impaired vasorelaxation. Circulation. 2006;113:2818-2825.
14. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Thromboxane a2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension. 1990;15:699-703.
15. Ito T, Kato T, Iwama Y, et al. Prostaglandin h2 as an endotheliumderived contracting factor and its interaction with endothelium-derived nitric oxide. J Hypertens. 1991;9:729-736.
16. Shirahase H, Usui H, Manabe K, et al. An endothelium-dependent contraction induced by a-23187, a ca++ ionophore in canine basilar artery. J Pharmacol Exp Ther. 1988;247:701-705.
17. Gluais P, Lonchampt M, Morrow JD, et al. Acetylcholine-induced endothelium-dependent contractions in the shr aorta: the janus face of prostacyclin. Br J Pharmacol. 2005;146:834-845.
18. Rapoport RM, Williams SP. Role of prostaglandins in acetylcholineinduced contraction of aorta from spontaneously hypertensive and wistar-kyoto rats. Hypertension. 1996;28:64-75.
19. Janssen LJ, Tazzeo T. Involvement of tp and ep3 receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature. J Pharmacol Exp Ther. 2002;301:1060-1066.
20. Wong SL, Leung FP, Lau CW, et al. Cyclooxygenase-2-derived prostaglandin f2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res. 2009; 104:228-235.
21. Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension. 2004;44:381-386.
22. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
23. Kaelin WG Jr. Ros: really involved in oxygen sensing. Cell Metab. 2005;1:357-358.
24. Felty Q, Roy D. Mitochondrial signals to nucleus regulate estrogeninduced cell growth. Med Hypotheses. 2005;64:133-141.
25. Cai L, Li W, Wang G, et al. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome c-mediated caspase-3 activation pathway. Diabetes. 2002;51:1938-1948.
26. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol. 2004;287:R1014-R1030.
27. Fridovich I. Superoxide dismutases. Annu Rev Biochem. 1975;44:147-159.
28. Yang T, Poovaiah BW. Hydrogen peroxide homeostasis: activation of plant catalase by calcium/calmodulin. Proc Natl Acad Sci U S A. 2002; 99:4097-4102.
29. Matoba T, Shimokawa H, Kubota H, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun. 2002;290:909-913.
30. Matoba T, Shimokawa H, Nakashima M, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106:1521-1530.
31. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42: 1075-1081.
32. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Contractions to oxygenderived free radicals are augmented in aorta of the spontaneously hypertensive rat. Hypertension. 1989;13:859-864.
33. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of rhokinase suppresses angiotensin ii-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial nad(p)h oxidase system. Circ Res. 2003;93:767-775.
34. Henriksen EJ, Jacob S, Kinnick TR, et al. Selective angiotensin ii receptor antagonism reduces insulin resistance in obese zucker rats. Hypertension. 2001;38:884-890.
35. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358: 1547-1559.
36. Stanton A. Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2003;4:6-10.
37. Vaidyanathan S, Jarugula V, Dieterich HA, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008; 47:515-531.
38. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol. 2006;1:221-228.
39. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358: 2433-2446.
40. Didion SP, Sigmund CD, Faraci FM. Impaired endothelial function in transgenic mice expressing both human renin and human angiotensinogen. Stroke. 2000;31:760-764; discussion 765.
41. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46:569-576.
42. McMurray JJ, Abraham WT, Dickstein K, et al. Aliskiren, altitude, and the implications for atmosphere. Eur J Heart Fail. 2012;14:341-343.
43. Singh VP, Baker KM, Kumar R. Activation of the intracellular reninangiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol. 2008;294: H1675-H1684.
44. Singh VP, Le B, Khode R, et al. Intracellular angiotensin ii production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57:3297-3306.
45. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic tg(mren-2)27 rats. Hypertension. 2008;52:130-136.
46. Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008;52:563-572.
47. Corvol P, Michaud A, Soubrier F, et al. Recent advances in knowledge of the structure and function of the angiotensin i converting enzyme. J Hypertens Suppl. 1995;13:S3-S10.
48. Wei L, Alhenc-Gelas F, Soubrier F, et al. Expression and characterization of recombinant human angiotensin i-converting enzyme. Evidence for a c-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem. 1991; 266:5540-5546.
49. Linz W, Gohlke P, Unger T, et al. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction. Arch Mal Coeur Vaiss. 1995;88(spec no 2):31-34.
50. Ibrahim MM. Ras inhibition in hypertension. J Hum Hypertens. 2006; 20:101-108.
51. Linz W, Wohlfart P, Schoelkens BA, et al. Late treatment with ramipril increases survival in old spontaneously hypertensive rats. Hypertension. 1999;34:291-295.
52. Clozel M. Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension. Hypertension. 1991;18:II37-II42.
53. Berkenboom G, Brekine D, Unger P, et al. Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Hypertension. 1995; 26:738-743.
54. Garcia MP, Gimenez J, Serna M, et al. Effect of estrogen and angiotensinconverting enzyme inhibitor on vascular remodeling in ovariectomized spontaneously hypertensive rats. Menopause. 2006;13:397-403.
55. Ruggenenti P. Angiotensin-converting enzyme inhibition and angiotensin ii antagonism in nondiabetic chronic nephropathies. Semin Nephrol. 2004;24:158-167.
56. Hill C, Logan A, Smith C, et al. Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats. Diabetologia. 2001;44: 495-500.
57. Toblli JE, DeRosa G, Cao G, et al. Ace inhibitor and angiotensin type i receptor antagonist in combination reduce renal damage in obese zucker rats. Kidney Int. 2004;65:2343-2359.
58. O'Driscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest. 1997;100:678-684.
59. Arcaro G, Zenere BM, Saggiani F, et al. Ace inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care. 1999;22:1536-1542.
60. Cruden NL, Witherow FN, Webb DJ, et al. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol. 2004;24:1043-1048.
61. Xu J, Carretero OA, Shesely EG, et al. The kinin b1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol. 2009;94: 322-329.
62. Kitos TE, Choi CM, Cornell RB. Angiotensin stimulates phosphatidylcholine synthesis via a pathway involving diacylglycerol, protein kinase c, erk1/2, and ctp:phosphocholine cytidylyltransferase. Biochim Biophys Acta. 2006;1761:272-279.
63. Jung E, Betancourt-Calle S, Mann-Blakeney R, et al. Sustained phospholipase d activation in response to angiotensin ii but not carbachol in bovine adrenal glomerulosa cells. Biochem J. 1998;330(pt 1):445-451.
64. Schiffrin EL, Park JB, Intengan HD, et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101: 1653-1659.
65. Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens. 2003;16:123-128.
66. Hirooka Y, Kimura Y, Sagara Y, et al. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year followup in patients with essential hypertension. Clin Exp Hypertens. 2008;30: 267-276.
67. Yao EH, Fukuda N, Matsumoto T, et al. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res. 2007;30:1119-1128.
68. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2009;5: 301-314.
69. Cheetham C, Collis J, O'Driscoll G, et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulindependent diabetes. J Am Coll Cardiol. 2000;36:1461-1466.
70. Cheetham C, O'Driscoll G, Stanton K, et al. Losartan, an angiotensin type i receptor antagonist, improves conduit vessel endothelial function in type ii diabetes. Clin Sci (Lond). 2001;100:13-17.
71. Wong WT, Tian XY, Xu A, et al. Angiotensin ii type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid Redox Signal. 2010;13:757-768.
72. Babior BM. Nadph oxidase: an update. Blood. 1999;93:1464-1476.
73. Cai H, Griendling KK, Harrison DG. The vascular nad(p)h oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471-478.
74. Lassegue B, Clempus RE. Vascular nad(p)h oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277-R297.
75. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ang ii type 1 and 2 receptors on oxidative stress, renal nadph oxidase, and sod expression. Am J Physiol Regul Integr Comp Physiol. 2003;285:R117-R124.
76. Wingler K, Wunsch S, Kreutz R, et al. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med. 2001;31:1456-1464.
77. Engels F, Renirie BF, Hart BA, et al. Effects of apocynin, a drug isolated from the roots of picrorhiza kurroa, on arachidonic acid metabolism. FEBS Lett. 1992;305:254-256.
78. Baumer AT, Kruger CA, Falkenberg J, et al. The NAD(P)H oxidase inhibitor apocynin improves endothelial no/superoxide balance and lowers effectively blood pressure in spontaneously hypertensive rats: comparison to calcium channel blockade. Clin Exp Hypertens. 2007;29: 287-299.
79. Li RH, Wozney JM. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. 2001;19:255-265.
80. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev. 1996;6:432-438.
81. Miyazono K, Maeda S, Imamura T. Bmp receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005;16:251-263.
82. Yang X, Long L, Southwood M, et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res. 2005;96:1053-1063.
83. Wong WT, Tian XY, Chen Y, et al. Bone morphogenic protein-4 impairs endothelial function through oxidative stress-dependent cyclooxygenase- 2 upregulation: implications on hypertension. Circ Res. 2010;107:984-991.
84. Vendrov AE, Madamanchi NR, Hakim ZS, et al. Thrombin and Nad (P)H oxidase-mediated regulation of CD44 and BMP4-id pathway in VSMC, restenosis, and atherosclerosis. Circ Res. 2006;98:1254- 1263.
85. Chang K, Weiss D, Suo J, et al. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis. Circulation. 2007;116: 1258-1266.
86. Valdimarsdottir G, Goumans MJ, Rosendahl A, et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation. 2002;106:2263-2270.
87. Bostrom KI, Jumabay M, Matveyenko A, et al. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res. 2011;108:446-457.
88. Zhou J, Lee PL, Tsai CS, et al. Force-specific activation of smad1/5 regulates vascular endothelial cell cycle progression in response to disturbed flow. Proc Natl Acad Sci U S A. 2012;109:7770-7775.
89. Bostrom K, Watson KE, Horn S, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91: 1800-1809.
90. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998-2003.
91. Schluesener HJ, Meyermann R. Immunolocalization of BMP-6, a novel TGF-beta-related cytokine, in normal and atherosclerotic smooth muscle cells. Atherosclerosis. 1995;113:153-156.
92. White E. Life, death, and the pursuit of apoptosis. Genes Dev. 1996;10: 1-15.
93. Hetts S. To die or not to die: an overview of apoptosis and its role in disease. JAMA. 1998;279:300-307.
94. Bauriedel G, Hutter R, Welsch U, et al. Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability. Cardiovasc Res. 1999;41:480-488.
95. Okura T, Watanabe S, Jiang Y, et al. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens. 2002;20:895-898.
96. Ho FM, Liu SH, Liau CS, et al. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation. 2000;101:2618- 2624.
97. Choy J, Granville D, Hunt D, et al. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol. 2001;33:1673-1690.
98. Tricot O, Mallat Z, Heymes C, et al. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation. 2000;101:2450-2453.
99. Tian XY, Yung LH, Wong WT, et al. Bone morphogenic protein-4 induces endothelial cell apoptosis through oxidative stress-dependent p38mapk and jnk pathway. J Mol Cell Cardiol. 2012;52:237-244.
100. Csiszar A, Ahmad M, Smith KE, et al. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am J Pathol. 2006; 168:629-638.
101. Maloney E, Sweet IR, Hockenbery DM, et al. Activation of NF- {kappa}b by palmitate in endothelial cells. A key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol. 2009;29:1370-1375.
102. Csiszar A, Labinskyy N, Jo H, et al. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. Am J Physiol Heart Circ Physiol. 2008;295:H569-H577.
103. San Martin A, Du P, Dikalova A, et al. Reactive oxygen species-selective regulation of aortic inflammatory gene expression in type 2 diabetes. Am J Physiol Heart Circ Physiol. 2007;292:H2073-H2082.
104. Csiszar A, Smith KE, Koller A, et al. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappab activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation. 2005;111:2364-2372.
105. Frank DB, Abtahi A, Yamaguchi DJ, et al. Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res. 2005;97:496-504.
106. Yang J, Davies RJ, Southwood M, et al. Mutations in bone morphogenetic protein type ii receptor cause dysregulation of id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res. 2008;102: 1212-1221.
107. Goulley J, Dahl U, Baeza N, et al. Bmp4-bmpr1a signaling in beta cells is required for and augments glucose-stimulated insulin secretion. Cell Metab. 2007;5:207-219.
108. Scott GJ, Ray MK, Ward T, et al. Abnormal glucose metabolism in heterozygous mutant mice for a type i receptor required for BMP signaling. Genesis. 2009;47:385-391.
109. Bottcher Y, Unbehauen H, Kloting N, et al. Adipose tissue expression and genetic variants of the bone morphogenetic protein receptor 1a gene (bmpr1a) are associated with human obesity. Diabetes. 2009;58: 2119-2128.
110. Tominaga T, Abe H, Ueda O, et al. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J Biol Chem. 2011;286:20109-20116.
111. Tang EH, Vanhoutte PM. Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther. 2009;122:140-149.
112. Shi Y, So KF, Man RY, et al. Oxygen-derived free radicals mediate endothelium-dependent contractions in femoral arteries of rats with streptozotocin-induced diabetes. Br J Pharmacol. 2007;152:1033-1041.
113. Yang D, Feletou M, Boulanger CM, et al. Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol. 2002;136:104-110.
114. Baber SR, Champion HC, Bivalacqua TJ, et al. Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds. Circulation. 2003;108:896-901.
115. Therland KL, Stubbe J, Thiesson HC, et al. Cycloxygenase-2 is expressed in vasculature of normal and ischemic adult human kidney and is colocalized with vascular prostaglandin e2 ep4 receptors. J Am Soc Nephrol. 2004;15:1189-1198.
116. Bagi Z, Erdei N, Toth A, et al. Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of cox-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol. 2005;25:1610-1616.
117. Bagi Z, Erdei N, Papp Z, et al. Up-regulation of vascular cyclooxygenase-2 in diabetes mellitus. Pharmacol Rep. 2006;58(suppl):52-56.
118. Hartner A, Cordasic N, Goppelt-Struebe M, et al. Role of macula densa cyclooxygenase-2 in renovascular hypertension. Am J Physiol Ren Physiol. 2003;284:F498-F502.
119. Katusic ZS, Vanhoutte PM. Superoxide anion is an endotheliumderived contracting factor. Am J Physiol. 1989;257:H33-H37.
120. Barbieri SS, Weksler BB. Tobacco smoke cooperates with interleukin- 1beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo. FASEB J. 2007;21:1831-1843.
121. Flavahan NA. Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci. 2007;28:106-110.
122. Zou MH, Daiber A, Peterson JA, et al. Rapid reactions of peroxynitrite with heme-thiolate proteins as the basis for protection of prostacyclin synthase from inactivation by nitration. Arch Biochem Biophys. 2000; 376:149-155.
123. Zou MH, Shi C, Cohen RA. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin h(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes. 2002;51:198-203.
124. Stahl R, Dienemann H, Besserer K, et al. Effect of indomethacin on blood pressure in rats with renovascular hypertension: dependence on plasma renin activity. Klin Wochenschr. 1981;59:245-246.
125. Imanishi M, Kawamura M, Akabane S, et al. Aspirin lowers blood pressure in patients with renovascular hypertension. Hypertension. 1989;14:461-468.
126. Boussairi EH, Sacquet J, Sassard J, et al. Thromboxane a2-prostaglandin h2 and renovascular hypertension in rats. Am J Physiol. 1994;267: R1190-R1197.
127. Fortes ZB, Costa SG, Nigro D, et al. Effect of indomethacin on the microvessel reactivity of two-kidney, one-clip hypertensive rats. Arch Int Pharmacodyn Ther. 1992;316:75-89.
128. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
129. Tian XY, Wong WT, Leung FP, et al. Oxidative stress-dependent cyclooxygenase-2-derived prostaglandin f(2alpha) impairs endothelial function in renovascular hypertensive rats. Antioxid Redox Signal. 2012;16:363-373.
130. Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase c and reactive oxygen species. Circulation. 2003;107:1017-1023.
131. Sheu ML, Ho FM, Yang RS, et al. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vasc Biol. 2005;25: 539-545.
132. Guo Z, Su W, Allen S, et al. Cox-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc Res. 2005;67:723-735.
133. Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stressactivated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599-622.
134. Chenevard R, Hurlimann D, Bechir M, et al. Selective cox-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-409.
135. McAdam BF, Byrne D,Morrow JD, et al. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane a2 and prostacyclin in cigarette smokers. Circulation. 2005;112:1024-1029.
136. Widlansky ME, Price DT, Gokce N, et al. Short- and long-term cox-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003;42:310-315.